Gina Tomaine

News
Teclistamab Induces Deep and Durable Responses in Triple–Class-Exposed Relapsed/Refractory MM
07/13/2022
Teclistamab, a T-cell–redirecting bispecific antibody, showed promising efficacy in treating patients with triple-class–exposed relapsed or refractory MM, inducing deep and durable responses in a recent study.
Teclistamab, a T-cell–redirecting bispecific antibody, showed promising efficacy in treating patients with triple-class–exposed relapsed or refractory MM, inducing deep and durable responses in a recent study.
Teclistamab, a...
07/13/2022
Oncology
News
FDA Grants Expedited Approval to Quizartinib for Patients With Newly Diagnosed AML With FLT3/ITD Mutations
07/24/2023
The FDA granted approval to quizartinib for patients with newly diagnosed FLT3/ITD-positive acute myeloid leukemia, as detected by an FDA-approved test.
The FDA granted approval to quizartinib for patients with newly diagnosed FLT3/ITD-positive acute myeloid leukemia, as detected by an FDA-approved test.
The FDA granted approval to...
07/24/2023
Oncology
News
Ibrutinib Plus Bendamustine and Rituximab Prolongs PFS in Older Patients with MCL
08/02/2022
Ibrutinib added to bendamustine and rituximab followed by rituximab maintenance yields significantly longer PFS vs placebo in older patients with previously untreated MCL, according to findings from the phase 3 SHINE trial.
Ibrutinib added to bendamustine and rituximab followed by rituximab maintenance yields significantly longer PFS vs placebo in older patients with previously untreated MCL, according to findings from the phase 3 SHINE trial.
Ibrutinib added to bendamustine...
08/02/2022
Oncology
News
Jaktinib Improves Clinical Symptoms in JAK Inhibitor-Naïve Patients With Myelofibrosis
09/20/2022
Jaktinib reduces spleen volume and improves anemia and other clinical symptoms with acceptable tolerability in JAK inhibitor-naïve patients with myelofibrosis, according to results from a phase 2 trial.
Jaktinib reduces spleen volume and improves anemia and other clinical symptoms with acceptable tolerability in JAK inhibitor-naïve patients with myelofibrosis, according to results from a phase 2 trial.
Jaktinib reduces spleen volume...
09/20/2022
Oncology
News
PILOT Trial Supports Lisocabtagene Maraleucel as Second-Line Therapy for Relapsed/Refractory LBCL
09/02/2022
Lisocabtagene maraleucel demonstrates promising safety and efficacy as a second-line treatment for patients with LBCL not eligible for hematopoietic stem-cell transplantation, according to findings from the PILOT trial.
Lisocabtagene maraleucel demonstrates promising safety and efficacy as a second-line treatment for patients with LBCL not eligible for hematopoietic stem-cell transplantation, according to findings from the PILOT trial.
Lisocabtagene maraleucel...
09/02/2022
Oncology
News
CD19 CAR T-Cell Product Type Impact on Outcomes in Relapsed/Refractory Non-Hodgkin Lymphoma
08/02/2022
Study findings suggest that CD19 CAR T-cell product type, among axicabtagene ciloleucel, tisagenlecleucel, and JCAR014, independently impacts toxicity and efficacy in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Study findings suggest that CD19 CAR T-cell product type, among axicabtagene ciloleucel, tisagenlecleucel, and JCAR014, independently impacts toxicity and efficacy in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Study findings suggest that CD19...
08/02/2022
Oncology
News
MRD-Guided Quadruplet Regimen Associated With Deep, Durable Responses in MM
08/10/2022
An MRD-adapted study design using elotuzumab with weekly carfilzomib, lenalidomide, and dexamethasone without transplant was associated with deep, durable responses in patients with MM.
An MRD-adapted study design using elotuzumab with weekly carfilzomib, lenalidomide, and dexamethasone without transplant was associated with deep, durable responses in patients with MM.
An MRD-adapted study design...
08/10/2022
Oncology
News
Evaluating Long-Term Clinical Efficacy of ESAs Among Patients With Low‑Risk or Intermediate‑1‑Risk MDS
09/11/2023
Erythropoiesis‑stimulating agent efficacy began to plateau after the 24th month of therapy among patients with low‑risk or intermediate‑1‑risk MDS, followed by a decrease in response rates, according to data presented at the SOHO 2023 annual...
Erythropoiesis‑stimulating agent efficacy began to plateau after the 24th month of therapy among patients with low‑risk or intermediate‑1‑risk MDS, followed by a decrease in response rates, according to data presented at the SOHO 2023 annual...
Erythropoiesis‑stimulating agent...
09/11/2023
Oncology
News
Momelotinib Associated With Positive Survival Outcomes in Patients With Myelofibrosis: SIMPLIFY Trials
08/04/2022
In the phase 3 SIMPLIFY trials, momelotinib demonstrated excellent OS and leukemia-free survival in patients with myelofibrosis, as well as activity against anemia, symptoms, and splenomegaly.
In the phase 3 SIMPLIFY trials, momelotinib demonstrated excellent OS and leukemia-free survival in patients with myelofibrosis, as well as activity against anemia, symptoms, and splenomegaly.
In the phase 3 SIMPLIFY trials,...
08/04/2022
Oncology
News
Long-Term Results of ASCT in Adult High-Risk Acute Lymphoblastic Leukemia
09/13/2022
Matched sibling and unrelated donor-based allogeneic hematopoietic stem cell transplantations in patients with BCR-ABL-negative acute lymphoblastic leukemia yielded similar long-term outcomes.
Matched sibling and unrelated donor-based allogeneic hematopoietic stem cell transplantations in patients with BCR-ABL-negative acute lymphoblastic leukemia yielded similar long-term outcomes.
Matched sibling and unrelated...
09/13/2022
Oncology

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
SAWC Spring
April 30 ⁠–⁠ May 4
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use